Using a similar dosing schedule (albeit with higher doses), ABT-263 mirrored A-1331852 in terms of efficacy alone and in combination with Cisplatin (Fig. S9A–C), weight maintenance (Fig. S9D), reversible thrombocytopaenia, (Fig. S9E), and ex vivo analyses of markers of apoptosis (Fig. S9F), proliferation (Fig. S9G), and changes in BCL-2 family protein expression (Fig. S10A, B). Here, BCL2 is linked to Thrombocytopenia.